Apnimed To Participate In Upcoming September Investor Conferences

(MENAFN- PR Newswire)

CAMBRIDGE, Mass, Sept. 15, 2025 /PRNewswire/ -- Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drugs that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced that management will be participating in the following investor conferences taking place in September.

Details of Apnimed's participation are as follows:

Event : Bank of America Healthcare Trailblazers Private Company Conference
Date : September 17, 2025

Event : Chardan Capital Markets Sleep Disorder Day 2025
Date : September 22, 2025
To register to participate in the Chardan Capital Markets Sleep Disorder Day 2025, please do so here: Attendee Information

Apnimed will be hosting 1x1 investor meetings around these events. Investors interested in meeting with Apnimed should contact their Bank of America and Chardan Capital Markets representatives, respectively, directly.

About Apnimed
Apnimed is a privately held, clinical-stage pharmaceutical company based in Cambridge, Massachusetts, dedicated to transforming the treatment landscape for sleep-related breathing diseases. We believe the introduction of simple, once-nightly oral drugs may dramatically expand diagnosis and the reach of treatment for people with OSA. OSA, like other common chronic diseases such as diabetes or hypertension, would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people get the oxygen and restorative sleep needed to thrive.

Apnimed is advancing a robust pipeline of oral pharmaceutical product candidates designed to improve oxygenation in individuals living with OSA and other chronic sleep-related breathing diseases. Our lead candidate, AD109, could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. Apnimed is also developing several therapies as part of its joint venture with Shionogi & Co., Ltd., Shionogi-Apnimed Sleep Science. Learn more at apnimed or follow us on X and LinkedIn.

Media Contact: [email protected]
Investor Contact: [email protected]

SOURCE Apnimed, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN15092025003732001241ID1110062668